Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | AHR | P35869 | 2/20 | 0.54 |
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | KIF11 | P52732 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28797 | 1.00 | CA4 (0.54) | CA4AHRLTA4HKIF11KCNH2 | |
| SCHEMBL12199475 | 0.92 | KIF11 (0.56) | CA4AHRLTA4HKIF11KCNH2 | |
| SCHEMBL3855634 | 0.92 | ESR2 (0.53) | CA4AHRLTA4HKIF11KCNH2 | |
| SCHEMBL812742 | 0.91 | CA1 (0.58) | AHRLTA4HCES2CES1CA12 | |
| SCHEMBL8986531 | 0.89 | AHR (0.57) | AHRKIF11KCNH2ACSS2LMNA | |
| SCHEMBL18383079 | 0.88 | LTA4H (0.55) | CA4AHRLTA4HKIF11KCNH2 | |
| SCHEMBL8824303 | 0.88 | CA1 (0.67) | CES2CES1CA1CA2LMNA | |
| SCHEMBL18027607 | 0.88 | LTA4H (0.50) | AHRLTA4HKIF11KCNH2ACSS2 | |
| SCHEMBL18387604 | 0.88 | ACSS2 (0.50) | AHRLTA4HKIF11KCNH2ACSS2 | |
| SCHEMBL7763666 | 0.87 | CA4 (0.54) | CA4LTA4HKIF11KCNH2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 495 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312630-A1 | PHOSPHORAMIDITE SYNTHESIS ON-DEMAND | AARHUS UNIVERSITET (DK) | 2023-10-05 | — | — | US | claimed |
| EP-4182325-A1 | PHOSPHORAMIDITE SYNTHESIS ON-DEMAND | Aarhus Universitet (DK) | 2023-05-24 | — | — | EP | claimed |
| US-20220304980-A1 | METERED DOSING COMPOSITIONS AND METHODS OF USE OF PSYCHEDELIC COMPOUNDS | MARLEY GREEN, LLC | 2022-09-29 | — | — | US | claimed |
| WO-2022013393-A1 | PHOSPHORAMIDITE SYNTHESIS ON-DEMAND | AARHUS UNIVERSITET (DK) | 2022-01-20 | — | — | WO | claimed |
| CN-112430179-A | High-efficiency separation and purification method of 4,4 '-dimethoxytriphenylchloromethane and 4,4' -dimethoxytrityl alcohol | 连云港冠昕医药科技有限公司 | 2021-03-02 | — | — | CN | claimed |
| EP-1975256-B1 | Modified oligonucleotides for mismatch discrimination | EPOCH BIOSCIENCES INC (US) | 2012-07-11 | — | — | EP | claimed |
| EP-1261616-B1 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | EPOCH BIOSCIENCES INC (US) | 2010-08-18 | — | — | EP | claimed |
| EP-1975256-A1 | Modified oligonucleotides for mismatch discrimination | Epoch Biosciences, Inc. (US) | 2008-10-01 | — | — | EP | claimed |
| US-7045610-B2 | Modified oligonucleotides for mismatch discrimination | EPOCH BIOSCIENCES, INC. (US) | 2006-05-16 | — | — | US | claimed |
| US-20060009628-A1 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | ELITECHGROUP, INC. | 2006-01-12 | — | — | US | claimed |
| US-5204218-A | Triphenylmethanol photobase generators and base-catalytic reaction compound | MITSUBISHI DENKI KABUSHIKI KAISHA (JP) | 1993-04-20 | — | — | US | claimed |
| CN-122094698-A | Ligands for extrahepatic delivery of siRNA | — | 2026-05-26 | — | — | CN | disclosed |
| US-12590330-B2 | Methods for indexing samples and sequencing multiple polynucleotide templates | ILLUMINA CAMBRIDGE LIMITED (GB) | 2026-03-31 | — | — | US | disclosed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | disclosed |
| US-12378276-B2 | Convergent liquid phase syntheses of oligonucleotides | BIOGEN MA INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-0164054-A1 | Method for detection of polymorphic restriction sites and nucleic acid sequences | CETUS CORPORATION (US) | 1985-12-11 | — | — | EP | disclosed |
| EP-0130564-A1 | Modified (80-113) beta interferons | G.D. Searle & Co. (US) | 1985-01-09 | — | — | EP | disclosed |
| EP-0130565-A1 | Modified (115-145) beta interferons | G.D. Searle & Co. (US) | 1985-01-09 | — | — | EP | disclosed |
| EP-0130566-A1 | Modified (1-28) beta interferons | G.D. Searle & Co. (US) | 1985-01-09 | — | — | EP | disclosed |
| EP-0068375-A2 | Recombinant DNA techniques for the production of relaxin | G.D. Searle & Co. (US) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312630-A1 | PHOSPHORAMIDITE SYNTHESIS ON-DEMAND | RNGTT, PPA1, PNP | CA4 3126/4885AHR 4538/4885LTA4H 1374/4885 |
| US-12378276-B2 | Convergent liquid phase syntheses of oligonucleotides | RTCB, RNGTT, POLR2H | CA4 1773/4885AHR 4854/4885LTA4H 2451/4885 |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | BDNF, NTRK2, GRIN2A | CA4 4840/4885AHR 1671/4885LTA4H 3732/4885 |
| US-20060009628-A1 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | MSH2, RNGTT, DCLRE1B | CA4 3519/4885AHR 2142/4885LTA4H 4413/4885 |
| US-12590330-B2 | Methods for indexing samples and sequencing multiple polynucleotide templates | POLRMT, SSBP1, MAVS | CA4 4558/4885AHR 3013/4885LTA4H 4657/4885 |
| US-20220304980-A1 | METERED DOSING COMPOSITIONS AND METHODS OF USE OF PSYCHEDELIC COMPOUNDS | PNMT, CRH, HTR5A | CA4 3778/4885AHR 164/4885LTA4H 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.